Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity
This cross-sectional study examines the US prescribing trends of glucagon-like peptide 1 (GLP-1) receptor agonists among individuals with type 2 diabetes and/or obesity.
Authors
- Piaopiao Li (ORCID: https://orcid.org/0000-0003-0941-5563)
- Megha Shah (ORCID: https://orcid.org/0000-0002-6722-7846)
- Rodolfo Javier Galindo (ORCID: https://orcid.org/0000-0002-9295-3225)
- Francisco J. Pasquel (ORCID: https://orcid.org/0000-0002-3845-6703)
- Jithin Sam Varghese (ORCID: https://orcid.org/0000-0003-3825-9897)
- Hui Shao (ORCID: https://orcid.org/0000-0002-4088-546X)
- Mohammed K. Ali (ORCID: https://orcid.org/0000-0001-7266-2503)
Institutions
- University of Miami (US)
- Emory University (US)
- University of Florida (US)
- Woodruff Health Sciences Center (US)
- Florida College (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.40890
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36